Automaker Stellantis Names New Chief Executive Officer
Stellantis (STLA), the world’s fourth-largest automaker, has named Italian automotive executive Antonio Filosa as its new chief executive officer (CEO).Filosa replaces former CEO Carlos Tavares, who resigned last year under pressure from the company’s board of directors.Filosa, who is currently Stellantis’ chief operating officer (COO) for the Americas, will take the helm of the car company on June 23.The appointment returns Stellantis, which was created from the 2021 merger of France’s PSA Peugeot and Italian-U.S. carmaker Fiat Chrysler, to Italian hands.John Elkann, heir to the Fiat-founding Agnelli family, remains chairman of Stellantis, whose automotive brands include Chrysler, Dodge and Jeep.In a news release, Stellantis said that the board’s choice was unanimous and called Filosa a “natural choice” due to his leadership track record and knowledge of the auto business.Filosa joined Fiat in 1999, spending much of his career in Latin America where he held positions from plant manager to head of purchasing and later chief operating officer. He was promoted to chief operating officer of the Americas in 2024 in an executive shake-up as sales slumped in North America, the company’s main profit centre.Stellantis has been lagging its competitors in the transition to electric vehicles and facing stiff competition from Chinese automakers. The stock of Stellantis has declined 18% this year to trade at $10.48 U.S. per share in New York.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


